نتایج جستجو برای: leucovorin

تعداد نتایج: 2615  

Journal: :Cancer research 1981
J A Straw J M Covey D Szapary

The pharmacokinetics of d- and l-citrovorum factor (CF) are quite different with respect to the postdistributional plasma decay rates. The natural (l) isomer had a half-life (beta) of 47 +/- 4 (S.E.) min compared to 143 +/- 15 min for the unnatural (d) isomer. Renal clearance was the same for both isomers and was proportional to glomerular filtration rate. Urinary excretion appeared to be the o...

Journal: :Annales pharmaceutiques francaises 2013
J Vigneron A Astier R Trittler J D Hecq M Daouphars I Larsson B Pourroy F Pinguet

The recommendations for the practical stability of anticancer drugs published in 2010 by the French Society of Hospital Pharmacists (SFPO) and the European Society of Oncology Pharmacists (ESOP) have been updated. Ten new molecules have been included (asparaginase, azacitidine, bevacizumab, clofarabine, eribuline mesylate, folinate sodium, levofolinate calcium, nelarabine, rituximab, temsirolim...

Journal: :Cancer research 1952
H E SKIPPER C NOLAN M A NEWTON L SIMPSON

It has been observed that folie acid (2) or citrovorum factor (1) will prevent the anti-leukemic ac tion of folie acid antagonists. We have reported that desoxyribonucleic acid (5) and vitamin Bi2 (7) will partially prevent the anti-leukemic action of 4-aminopteroylglutamic acids, and have more re cently observed that a combination of thymidine, adenylic, guanylic, and cytidylic acids or DNA pl...

Journal: :Journal of Korean Medical Science 1993
S. Y. Lee D. G. Jeon S. S. Kim J. J. Jang K. J. Cho

During the last decade, many clinical investigators at various cancer centers have reported the efficacy of various chemotherapeutic agents in the treatment of osteosarcoma. The regimens using high-dose methotrexate (HDMTX) with citrovorum factor rescue are now considered to be one of the most effective treatments of choice. From December 1989 to May 1991, sixteen patients with Enneking's stage...

Journal: :Clinical journal of oncology nursing 2016
Lisa Kennedy Sheldon

The patient, R.C., finished her chemotherapy for breast cancer on June 4, 2007. At 58, she was ready for a better year, putting cancer treatment behind her and beginning her new life after cancer. In 2014, I was surprised to see R.C. on the schedule for chemotherapy education for 
FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin). Colorectal cancer had been discovered during a routine ...

Journal: :The Journal of biological chemistry 1954
H G STEINMAN V I OYAMA H O SCHULZE

A chemically defined medium was described in a previous paper (1) which, when supplemented with crystallized serum albumin, permitted sustained growth of the Reiter treponeme. When an attempt was made to cultivate other saprophytic strains of Treponema pallidurn on this medium, a number failed to grow. One of these strains, S-69,’ could be cultivated if the synthetic medium were supplemented wi...

2013
Ying-dong Cheng Hua Yang Guo-qing Chen Zhi-cao Zhang

The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a substantial improvement in the overall survival rate. These drugs are capable of specifically targeting the inherent abnormal pathways in cancer cells, which are potentially less toxic than traditional nonselective c...

2013
A. Azmy S. Abdelwahab M. Yassen

Objective. Comparing activity of 2 regimens combining oxaliplatin to bolus modulated fluorouracil as second line treatment in advanced pancreatic adenocarcinoma pretreated with gemcitabine-containing schedule. Methods. Forty eight patients with advanced pancreatic adenocarcinoma were randomly assigned to receive either FU 500 mg/m(2) IV bolus weekly ×6 weeks plus leucovorin 500 mg/m(2) IV weekl...

2010
C.L. Attard J.A. Maroun K. Alloul D.T. Grima L.M. Bernard

OBJECTIVE The cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5FU/LV)-the FOLFOX regimen-was compared with that of 5FU/LV alone as adjuvant therapy for patients with stage III colon cancer, from the perspective of the Cancer Care Ontario New Drug Funding Program. In the mosaic (Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuv...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید